Pharmacokinetics, Safety and Tolerability of Single-dose or Multiple-dose Cefiderocol in Hospitalized Pediatric Patients Three Months to Less Than Eighteen Years Old With Infections Treated With Standard-of-care Antibiotics in the PEDI-CEFI Phase 2 Study.
Journal
The Pediatric infectious disease journal
ISSN: 1532-0987
Titre abrégé: Pediatr Infect Dis J
Pays: United States
ID NLM: 8701858
Informations de publication
Date de publication:
04 Sep 2024
04 Sep 2024
Historique:
medline:
4
9
2024
pubmed:
4
9
2024
entrez:
4
9
2024
Statut:
aheadofprint
Résumé
Multidrug-resistant Gram-negative bacterial infections are increasing globally in neonates, infants and children; antibiotic options are limited. This international, multicenter, open-label phase 2 study, investigated the pharmacokinetics, safety and tolerability of single-dose and multiple-dose cefiderocol [as a 3-hour infusion (every 8 hours) dosed at 2000 mg for body weight ≥34 kg and at 60 mg/kg for body weight <34 kg], over a range of renal function, in hospitalized pediatric patients with aerobic Gram-negative bacterial infection; multiple-dose patients required standard-of-care systemic antibiotics for 5-14 days. Four cohorts of pediatric patients were enrolled (cohort 1: 12 to <18 years, cohort 2: 6 to <12 years, cohort 3: 2 to <6 years and cohort 4: 3 months to <2 years). A total of 53 patients (median age: 73.5 months) were enrolled. Plasma concentration profiles were similar with single-dose (n = 24) and multiple-dose (n = 29) cefiderocol, irrespective of age and body weight in those with normal renal function or mild renal impairment. Geometric mean concentrations at the end of infusion ranged between 72.7 and 97.1 μg/mL for single-dose cefiderocol and between 88.8 and 106.0 μg/mL after multiple doses. At 8 hours, corresponding trough concentrations ranged from 7.86 to 10.8 μg/mL with single-dose cefiderocol and from 9.64 to 18.1 μg/mL with multiple doses. There were no deaths, no cefiderocol-related serious adverse events, significant related laboratory abnormalities or discontinuations. Multiple-dose cefiderocol, administered for 5-14 days and according to body weight, achieved steady-state plasma concentrations that remained above the susceptibility breakpoints of Gram-negative bacteria throughout the dosing period. Cefiderocol was well tolerated.
Sections du résumé
BACKGROUND
BACKGROUND
Multidrug-resistant Gram-negative bacterial infections are increasing globally in neonates, infants and children; antibiotic options are limited.
METHODS
METHODS
This international, multicenter, open-label phase 2 study, investigated the pharmacokinetics, safety and tolerability of single-dose and multiple-dose cefiderocol [as a 3-hour infusion (every 8 hours) dosed at 2000 mg for body weight ≥34 kg and at 60 mg/kg for body weight <34 kg], over a range of renal function, in hospitalized pediatric patients with aerobic Gram-negative bacterial infection; multiple-dose patients required standard-of-care systemic antibiotics for 5-14 days. Four cohorts of pediatric patients were enrolled (cohort 1: 12 to <18 years, cohort 2: 6 to <12 years, cohort 3: 2 to <6 years and cohort 4: 3 months to <2 years).
RESULTS
RESULTS
A total of 53 patients (median age: 73.5 months) were enrolled. Plasma concentration profiles were similar with single-dose (n = 24) and multiple-dose (n = 29) cefiderocol, irrespective of age and body weight in those with normal renal function or mild renal impairment. Geometric mean concentrations at the end of infusion ranged between 72.7 and 97.1 μg/mL for single-dose cefiderocol and between 88.8 and 106.0 μg/mL after multiple doses. At 8 hours, corresponding trough concentrations ranged from 7.86 to 10.8 μg/mL with single-dose cefiderocol and from 9.64 to 18.1 μg/mL with multiple doses. There were no deaths, no cefiderocol-related serious adverse events, significant related laboratory abnormalities or discontinuations.
CONCLUSIONS
CONCLUSIONS
Multiple-dose cefiderocol, administered for 5-14 days and according to body weight, achieved steady-state plasma concentrations that remained above the susceptibility breakpoints of Gram-negative bacteria throughout the dosing period. Cefiderocol was well tolerated.
Identifiants
pubmed: 39230271
doi: 10.1097/INF.0000000000004529
pii: 00006454-990000000-00999
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2024 The Author(s). Published by Wolters Kluwer Health, Inc.
Références
Venuti F, Romani L, De Luca M, et al. Novel beta lactam antibiotics for the treatment of multidrug-resistant Gram-negative infections in children: a narrative review. Microorganisms. 2023;11:1798.
Bilen NM, Sahbudak Bal Z, Güner Özenen G, et al. Risk factors for infection and mortality associated with Stenotrophomonas maltophilia bloodstream infections in children; comparison with Pseudomonas aeruginosa bloodstream infections. Pediatr Infect Dis J. 2023;42:374–380.
Chiusaroli L, Liberati C, Caseti M, et al. Therapeutic options and outcomes for the treatment of neonates and preterms with Gram-negative multidrug-resistant bacteria: a systematic review. Antibiotics (Basel). 2022;11:1088.
Yang Q, Kamat S, Mohamed N, et al. Antimicrobial susceptibility among Gram-negative isolates in pediatric patients in Latin America, Africa-Middle East, and Asia from 2016-2020 compared to 2011-2015: results from the ATLAS Surveillance Study. J Pediatric Infect Dis Soc. 2023;12:459–470.
Russell NJ, Stohr W, Plakkal N, et al. Patterns of antibiotic use, pathogens, and prediction of mortality in hospitalized neonates and young infants with sepsis: a global neonatal sepsis observational cohort study (NeoOBS). PLoS Med. 2023;20:e1004179.
Doi Y. Treatment options for carbapenem-resistant Gram-negative bacterial infections. Clin Infect Dis. 2019;69:S565–S575.
Kaye KS, Naas T, Pogue JM, et al. Cefiderocol, a siderophore cephalosporin, as a treatment option for infections caused by carbapenem-resistant Enterobacterales. Infect Dis Ther. 2023;12:777–806.
Canton R, Doi Y, Simner PJ. Treatment of carbapenem-resistant Pseudomonas aeruginosa infections: a case for cefiderocol. Expert Rev Anti Infect Ther. 2022;20:1077–1094.
Olney KB, Thomas JK, Johnson WM. Review of novel β-lactams and β-lactam/β-lactamase inhibitor combinations with implications for pediatric use. Pharmacotherapy. 2023;43:713–731.
Avycaz (ceftazidime-avibactam for injection for intravenous use). Prescribing Information: Allergan USA Inc.; 2022.
Zerbaxa (ceftolozane-tazobactam). Prescribing Information: Merck; 2022.
Shortridge D, Streit JM, Mendes R, et al. In vitro activity of cefiderocol against US and European Gram-negative clinical isolates collected in 2020 as part of the SENTRY Antimicrobial Surveillance Program. Microbiol Spectr. 2022;10:e0271221.
Kollef M, Dupont H, Greenberg DE, et al. Prospective role of cefiderocol in the management of carbapenem-resistant Acinetobacter baumannii infections: review of the evidence. Int J Antimicrob Agents. 2023;62:106882.
Wise MG, Karlowsky JA, Hackel MA, et al. In vitro activity of cefiderocol against meropenem-nonsusceptible Gram-negative bacilli with defined β-lactamase carriage: SIDERO-WT surveillance studies, 2014-2019. Microb Drug Resist. 2023;29:360–370.
Fetcroja. Cefiderocol (1 g powder for concentrate for solution for infusion). Summary of Product Characteristics: Shionogi B.V.; 2020.
Fetroja. Cefiderocol for injection for intravenous use. Prescribing Information: Shionogi Inc.; 2021.
Aoki T, Yoshizawa H, Yamawaki K, et al. Cefiderocol (S-649266), a new siderophore cephalosporin exhibiting potent activities against Pseudomonas aeruginosa and other Gram-negative pathogens including multi-drug resistant bacteria: structure activity relationship. Eur J Med Chem. 2018;155:847–868.
Sato T, Yamawaki K. Cefiderocol: discovery, chemistry, and in vivo profiles of a novel siderophore cephalosporin. Clin Infect Dis. 2019;69(suppl 7):S538–S543.
Ito A, Sato T, Ota M, et al. In vitro antibacterial properties of cefiderocol, a novel siderophore cephalosporin, against Gram-negative bacteria. Antimicrob Agents Chemother. 2017;62:e01454–17.
Ito-Horiyama T, Ishii Y, Ito A, et al. Stability of novel siderophore cephalosporin S-649266 against clinically relevant carbapenemases. Antimicrob Agents Chemother. 2016;60:4384–4386.
Takemura M, Wise MG, Hackel MA, et al. In vitro activity of cefiderocol against MBL-producing Gram-negative bacteria collected in North America and Europe in five consecutive annual multinational SIDERO-WT surveillance studies (2014-2019). J Antimicrob Chemother. 2023;78:2019–2027.
Karlowsky JA, Hackel MA, Takemura M, et al. In vitro susceptibility of Gram-negative pathogens to cefiderocol in five consecutive annual multinational SIDERO-WT surveillance studies, 2014 to 2019. Antimicrob Agents Chemother. 2022;66:e0199021. Erratum in: Antimicrob Agents Chemother. 2023;67:e0042723.
Bianco G, Boattini M, Comini S, et al. Occurrence of multi-carbapenemases producers among carbapenemase-producing Enterobacterales and in vitro activity of combinations including cefiderocol, ceftazidime-avibactam, meropenem-vaborbactam, and aztreonam in the COVID-19 era. Eur J Clin Microbiol Infect Dis. 2022;41:573–580.
Bianco G, Boattini M, Comini S, et al. Activity of ceftolozane-tazobactam, ceftazidime-avibactam, meropenem-vaborbactam, cefiderocol and comparators against Gram-negative organisms causing bloodstream infections in Northern Italy (2019–2021): emergence of complex resistance phenotypes. J Chemother. 2022;34:302–310.
Coppi M, Antonelli A, Niccolai C, et al. Nosocomial outbreak by NDM-1-producing Klebsiella pneumoniae highly resistant to cefiderocol, Florence, Italy, August 2021 to June 2022. Euro Surveill. 2022;27:2200795.
Nguyen ST, DeJonge BLM, Bryowsky JJ, et al. Activity of cefiderocol and comparator agents against pediatric isolates of Enterobacterales, Pseudomonas aeruginosa, Acinetobacter baumannii-calcoaceticus species complex, and Stenotrophomonas maltophilia from the SENTRY Surveillance Program (2020-2022). Presented at IDWeek 2023, Boston, MA, October 11–15, 2023; Poster 2790.
Nakamura R, Ito-Horiyama T, Takemura M, et al. In vivo pharmacodynamic study of cefiderocol, a novel parenteral siderophore cephalosporin, in murine thigh and lung infection models. Antimicrob Agents Chemother. 2019;63:e02031–18.
Saisho Y, Katsube T, White S, et al. Pharmacokinetics, safety, and tolerability of cefiderocol, a novel siderophore cephalosporin for Gram-negative bacteria, in healthy subjects. Antimicrob Agents Chemother. 2018;62:02163–17.
Miyazaki S, Katsube T, Shen H, et al. Metabolism, excretion, and pharmacokinetics of [14C]-cefiderocol (S-649266), a siderophore cephalosporin, in healthy subjects following intravenous administration. J Clin Pharmacol. 2019;59:958–967.
Katsube T, Echols R, Arjona Ferreira JC, et al. Cefiderocol, a siderophore cephalosporin for Gram-negative bacterial infections: pharmacokinetics and safety in subjects with renal impairment. J Clin Pharmacol. 2017;57:584–591.
Katsube T, Echols R, Wajima T. Prediction of cefiderocol pharmacokinetics and probability of target attainment in pediatric subjects for proposing dose regimens. Open Forum Infect Dis. 2019;6:S330–S331.
Portsmouth S, van Veenhuyzen D, Echols R, et al. Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial. Lancet Infect Dis. 2018;18:1319–1328.
Wunderink RG, Matsunaga Y, Ariyasu M, et al. Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial. Lancet Infect Dis. 2021;21:213–225.
Bassetti M, Echols R, Matsunaga Y, et al. Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial. Lancet Infect Dis. 2021;21:226–240.
Alamarat ZI, Babic J, Tran TT, et al. Long-term compassionate use of cefiderocol to treat chronic osteomyelitis caused by extensively drug-resistant Pseudomonas aeruginosa and extended-spectrum-β-lactamase-producing Klebsiella pneumoniae in a pediatric patient. Antimicrob Agents Chemother. 2020;64:e01872–19.
Grasa CD, Gómez-Gil MR, San Román Pacheco S, et al. Compassionate use of cefiderocol for VIM metallo-β-lactamase-producing Pseudomonas aeruginosa infection in a toddler with Burkitt lymphoma. J Glob Antimicrob Resist. 2021;26:91–92.
Gainey AB, Burch AK, Brownstein MJ, et al. Combining bacteriophages with cefiderocol and meropenem/vaborbactam to treat a pan-drug resistant Achromobacter species infection in a pediatric cystic fibrosis patient. Pediatr Pulmonol. 2020;55:2990–2994.
Warner NC, Bartelt LA, Lachiewicz AM, et al. Cefiderocol for the treatment of adult and pediatric patients with cystic fibrosis and Achromobacter xylosoxidans infections. Clin Infect Dis. 2021;73:e1754–e1757.
Katsube T, Nicolau DP, Rodvold KA, et al. Intrapulmonary pharmacokinetic profile of cefiderocol in mechanically ventilated patients with pneumonia. J Antimicrob Chemother. 2021;76:2902–2905.
Matsumoto S, Singley CM, Hoover J, et al. Efficacy of cefiderocol against carbapenem-resistant Gram-negative bacilli in immunocompetent-rat respiratory tract infection models recreating human plasma pharmacokinetics. Antimicrob Agents Chemother. 2017;61:e00700–17.
Katsube T, Saisho Y, Shimada J, et al. Intrapulmonary pharmacokinetics of cefiderocol, a novel siderophore cephalosporin, in healthy adult subjects. J Antimicrob Chemother. 2019;74:1971–1974.
Monogue ML, Tsuji M, Yamano Y, et al. Efficacy of humanized exposures of cefiderocol (S-649266) against a diverse population of Gram-negative bacteria in a murine thigh infection model. Antimicrob Agents Chemother. 2017;61:e01022–17.
European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters. Version 13.0, 2023. Available at: http://www.eucast.org. Accessed November 14, 2023.
Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing, 33rd ed. CLSI Supplement M100: CLSI; 2023.